You are here

Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Berlin, , 10117 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Obstructive Pulmonary Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Post-bronchodilator FEV1/ FVC ratio of

- Post bronchodilator FEV1 of 50-80% (inclusive) of predicted.

- Body Mass Index (BMI) of less than 35 kg/m2; and a total body weight greater that 40
kg.

- Current smokers, or ex-smokers who have abstained from smoking for at least 6 months.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects having more than 2 exacerbations requiring treatment with oral steroids or
hospitalization for the treatment of COPD in the previous year.

- History of lower respiratory tract infection or significant disease instability during
the month preceding screening or during the period between screening and
randomization.

NCT00783406
Pfizer
Completed
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Chronic Obstructive Pulmonary Disease
NCT00472264
All Genders
40+
Years
St. Louis, Missouri
Chronic Obstructive Pulmonary Disease
NCT00219622
All Genders
40+
Years
Multiple Sites
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
NCT00138671
All Genders
30+
Years
Multiple Sites
Chronic Obstructive Pulmonary Disease
NCT02366637
All Genders
40+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now